Therefore, leading representatives of all pharmaceutical companies that produce incretin-based therapies were contacted directly in order to obtain the event numbers of acute pancreatitis across their phase III clinical trial programmes
Understanding these differences helps guide individualized management strategies, which are critical for maintaining adherence and optimizing outcomes
Beyond triglyceride reduction, the medication lowers blood pressure, reduces inflammation markers like C-reactive protein, and improves overall cholesterol ratios
However, this discrepancy between our post-marketing findings and the phase 3 trial results underscores the importance of ongoing pharmacovigilance and real-world evidence studies in identifying rare but potentially serious adverse effects that may not be captured in pre-approval clinical trials
Lequeux, I., Ducasse, E., Jouenne, T., and Thebault, P., Eur